Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gibbs

Showing results (281-290 of 292) with videos related to

Pageof 30
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 7, 2001
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferaseC J Dinsmore, J M Bergman, D D Wei, et al.
The AAPS Journal|February 4, 2025
Pharmaceutical Sciences: Insights and Observations from Academic Chairs and Vice ChairsKristy M Ainslie, Albert A Bowers, Robert H Chichewicz, et al.
Molecular and Cellular Biology|January 7, 1998
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosisR E Barrington, M A Subler, E Rands, et al.
Royal Society Open Science|September 15, 2023
The prelude to industrial whaling: identifying the targets of ancient European whaling using zooarchaeology and collagen mass-peptide fingerprintingYouri van den Hurk, Fanny Sikström, Luc Amkreutz, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of Medicinal Chemistry|March 29, 1996
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferaseT M Williams, T M Ciccarone, S C MacTough, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T Sisko, Thomas J Tucker, Mark T Bilodeau, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Cancer Research|May 29, 2000
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitorC A Omer, Z Chen, R E Diehl, et al.
Pageof 30

Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Bioorganic & Medicinal Chemistry Letters|March 7, 2001
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferaseC J Dinsmore, J M Bergman, D D Wei, et al.
The AAPS Journal|February 4, 2025
Pharmaceutical Sciences: Insights and Observations from Academic Chairs and Vice ChairsKristy M Ainslie, Albert A Bowers, Robert H Chichewicz, et al.
Molecular and Cellular Biology|January 7, 1998
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosisR E Barrington, M A Subler, E Rands, et al.
Royal Society Open Science|September 15, 2023
The prelude to industrial whaling: identifying the targets of ancient European whaling using zooarchaeology and collagen mass-peptide fingerprintingYouri van den Hurk, Fanny Sikström, Luc Amkreutz, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of Medicinal Chemistry|March 29, 1996
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferaseT M Williams, T M Ciccarone, S C MacTough, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T Sisko, Thomas J Tucker, Mark T Bilodeau, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Cancer Research|May 29, 2000
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitorC A Omer, Z Chen, R E Diehl, et al.
Pageof 30